Carbonic anhydrase inhibitors. Design of anticonvulsant sulfonamides incorporating indane moieties

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 23, 2004, Pages 5781-5786

  Chazalette, Celine ^a,b   Masereel, Bernard ^b   Rolin, Stéphanie ^b   Thiry, Anne ^b   Scozzafava, Andrea ^c   Innocenti, Alessio ^c   Supuran, Claudiu T ^c  

^a UNIV GRENOBLE ALPES   (France)

^b UNIVERSITY OF NAMUR   (Belgium)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 ACETAMIDO 5 SULFONAMIDOINDANE; 2 (2' METHOXY 5' CHLOROBENZENECARBONYL)AMINO 5 SULFONAMIDOINDANE; 2 (2',3',5',6' FLUOROBENZENECARBONYL)AMINO 5 SULFONAMIDOINDANE; 2 (4' CHLOROBENZENECARBONYL)AMINO 5 SULFONAMIDOINDANE; 2 (PENTAFLUOROBENZOYL)AMINO 5 SULFONAMIDOINDANE; 2 ACETAMIDO 5 SULFONAMIDOINDANE; 2 AMINO 5 SULFONAMIDOINDANE; 2 VALPROYLCARBOXAMIDO 5 SULFONAMIDOINDANE; ACETAZOLAMIDE; ANTICONVULSIVE AGENT; CARBONATE DEHYDRATASE INHIBITOR; METHAZOLAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; ERYTHROCYTE; FEMALE; HUMAN; MOUSE; NONHUMAN;

EID: 7244242690     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.09.061     Document Type: Article

References (20)

1. T. Mann, and D. Keilin Nature 146 1940 164 165
2. T.H. Maren Physiol. Rev. 47 1967 595 781
3. C.T. Supuran, A. Casini, and A. Scozzafava Development of Sulfonamide Carbonic Anhydrase Inhibitors (CAIs) C.T. Supuran A. Scozzafava J. Conway Carbonic Anhydraseâ€"Its Inhibitors and Activators 2004 CRC Press Boca Raton (FL), USA 67 148
4. C.T. Supuran, and A. Scozzafava Expert Opin. Ther. Pat. 10 2000 575 600
5. A. Scozzafava, A. Mastrolorenzo, and C.T. Supuran Expert Opin. Ther. Pat. 14 2004 667 702
6. C.T. Supuran, and A. Scozzafava Curr. Med. Chem.â€"Imm., Endoc. Metab. Agents 1 2001 61 97
7. M.A. Ilies, D. Vullo, J. Pastorek, A. Scozzafava, M. Ilies, M.T. Caproiu, S. Pastorekova, and C.T. Supuran J. Med. Chem. 46 2003 2187 2196
8. J.-Y. Winum, D. Vullo, A. Casini, J.-L. Montero, A. Scozzafava, and C.T. Supuran J. Med. Chem. 46 2003 5471 5477
9. X. de Leval, M. Ilies, A. Casini, J.-M. Dogné, A. Scozzafava, E. Masini, F. Mincione, M. Starnotti, and C.T. Supuran J. Med. Chem. 47 2004 2796 2804
10. D. Vullo, M. Franchi, E. Gallori, J. Antel, A. Scozzafava, and C.T. Supuran J. Med. Chem. 47 2004 1272 1279
11. J. Lehtonen, B. Shen, M. Vihinen, A. Casini, A. Scozzafava, C.T. Supuran, A.K. Parkkila, J. Saarnio, A.J. Kivela, A. Waheed, W.S. Sly, and S. Parkkila J. Biol. Chem. 279 2004 2719 2727
12. J.R. Casey, P.E. Morgan, D. Vullo, A. Scozzafava, A. Mastrolorenzo, and C.T. Supuran J. Med. Chem. 47 2004 2337 2347
13. F. Abbate, A. Casini, T. Owa, A. Scozzafava, and C.T. Supuran Bioorg. Med. Chem. Lett. 14 2004 217 223
14. B. Masereel, S. Rolin, F. Abbate, A. Scozzafava, and C.T. Supuran J. Med. Chem. 45 2002 312 320
15. M.A. Ilies, B. Masereel, S. Rolin, A. Scozzafava, G. Cîmpeanu, V. Câmpeanu, and C.T. Supuran Bioorg. Med. Chem. 12 2004 2717 2726
16. Bondinell, W. E.; Pendleton, R. G. U.S. Patent 4,192,888, 1980
17. 2-Acetamido-5-sulfonamidoindane 4: 2-aminoindane hydrochloride (25 g), sodium acetate (12 g), and acetic anhydride (200 mL) were stirred one night at room temperature. The evaporation of the mixture under reduce pressure led to a white powder, which was extracted from the aqueous phase using chloroform
18. -1 for CA II, respectively, based on Mr = 28.85 kDa for CA I and Mr = 29.30 kDa for CA II
19. R.G. Khalifah, D.J. Strader, S.H. Bryant, and S.M. Gibson Biochemistry 16 1977 2241 2247
20. 2 solutions in water at 20 °C were used as substrate. Stock solutions of inhibitor (1 mM) were prepared in distilled-deionized water with 10â€"20% (v/v) DMSO (which is not inhibitory at these concentrations) and dilutions up to 0.01 nM were done thereafter with distilled-deionized water. Inhibitor and enzyme solutions were preincubated together for 15 min at room temperature prior to assay, in order to allow for the formation of the Eâ€"I complex. Triplicate experiments were done for each inhibitor concentration, and the values reported throughout the paper are the mean of such results